# A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of VSA006 in Chinese NASH Patients

> **NCT06322628** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Visirna Therapeutics HK Limited** · enrollment: 48 (actual)

## Conditions studied

- Nash

## Interventions

- **DRUG:** VSA006
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06322628
- **Lead sponsor:** Visirna Therapeutics HK Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-22
- **Primary completion:** 2026-07
- **Final completion:** 2027-01
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06322628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06322628, "A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of VSA006 in Chinese NASH Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06322628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*